525 related articles for article (PubMed ID: 9538480)
21. Malignant hyperthermia: a review.
Johnson C; Edleman KJ
J Perinatol; 1992 Mar; 12(1):61-71. PubMed ID: 1560293
[TBL] [Abstract][Full Text] [Related]
22. Malignant hyperthermia.
Rosenberg H; Davis M; James D; Pollock N; Stowell K
Orphanet J Rare Dis; 2007 Apr; 2():21. PubMed ID: 17456235
[TBL] [Abstract][Full Text] [Related]
23. [Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil].
Almeida da Silva HC; Ferreira G; Rodrigues G; Santos JMD; Andrade PV; Hortense A; Vaz Perez M; Amaral JLGD
Braz J Anesthesiol; 2019; 69(2):152-159. PubMed ID: 30935497
[TBL] [Abstract][Full Text] [Related]
24. [Malignant hyperthermia--diagnostics, treatment and anaesthetic management].
Schuster F; Müller-Reible CR
Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Nov; 44(11-12):758-63; quiz 764. PubMed ID: 19918708
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs.
Schütte JK; Becker S; Burmester S; Starosse A; Lenz D; Kröner L; Wappler F; Gerbershagen MU
Eur J Anaesthesiol; 2011 Apr; 28(4):256-64. PubMed ID: 21513076
[TBL] [Abstract][Full Text] [Related]
26. Malignant hyperthermia testing in probands without adverse anesthetic reaction.
Timmins MA; Rosenberg H; Larach MG; Sterling C; Kraeva N; Riazi S
Anesthesiology; 2015 Sep; 123(3):548-56. PubMed ID: 26068069
[TBL] [Abstract][Full Text] [Related]
27. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines.
Glahn KPE; Bendixen D; Girard T; Hopkins PM; Johannsen S; Rüffert H; Snoeck MM; Urwyler A;
Br J Anaesth; 2020 Aug; 125(2):133-140. PubMed ID: 32591088
[TBL] [Abstract][Full Text] [Related]
28. [Malignant hyperthermia].
Zimprich F; Kress HG; Zeitlhofer J
Wien Klin Wochenschr; 2003 Sep; 115(15-16):556-62. PubMed ID: 14531168
[TBL] [Abstract][Full Text] [Related]
29. Malignant hyperthermia.
Denborough M
Lancet; 1998 Oct; 352(9134):1131-6. PubMed ID: 9798607
[TBL] [Abstract][Full Text] [Related]
30. Current understanding of malignant hyperthermia: genesis, prevention, and treatment.
Katz DN
CRNA; 1992 May; 3(2):54-63. PubMed ID: 1483145
[TBL] [Abstract][Full Text] [Related]
31. Malignant hyperthermia: current perspectives.
Felice-Johnson J; Sudds T; Bennett G
Am J Hosp Pharm; 1981 May; 38(5):646-51. PubMed ID: 7282692
[TBL] [Abstract][Full Text] [Related]
32. Suspected malignant hyperthermia in a 13-month-old: today's "typical" episode--a case report.
Smith CA; Carvill KA; Eckert T
AANA J; 1997 Jun; 65(3):247-9. PubMed ID: 9233094
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of malignant hyperthermia crisis during anesthesia].
Amiel I; Nivoche Y
Ann Fr Anesth Reanim; 1989; 8(5):427-34. PubMed ID: 2697157
[TBL] [Abstract][Full Text] [Related]
34. [Malignant hyperthermia: new developments in diagnosis and clinical management].
Dépret T; Krivosic-Horber R
Ann Fr Anesth Reanim; 2001 Dec; 20(10):838-52. PubMed ID: 11803844
[TBL] [Abstract][Full Text] [Related]
35. The severity of sevoflurane-induced malignant hyperthermia.
Migita T; Mukaida K; Kobayashi M; Hamada H; Kawamoto M
Acta Anaesthesiol Scand; 2012 Mar; 56(3):351-6. PubMed ID: 22092278
[TBL] [Abstract][Full Text] [Related]
36. Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic Review.
Larach MG; Klumpner TT; Brandom BW; Vaughn MT; Belani KG; Herlich A; Kim TW; Limoncelli J; Riazi S; Sivak EL; Capacchione J; Mashman D; Kheterpal S; Kooij F; Wilczak J; Soto R; Berris J; Price Z; Lins S; Coles P; Harris JM; Cummings KC; Berman MF; Nanamori M; Adelman BT; Wedeven C; LaGorio J; McCormick PJ; Tom S; Aziz MF; Coffman T; Ellis TA; Molina S; Peterson W; Mackey SC; van Klei WA; Ginde AA; Biggs DA; Neuman MD; Craft RM; Pace NL; Paganelli WC; Durieux ME; Nair BJ; Wanderer JP; Miller SA; Helsten DL; Turnbull ZA; Schonberger RB;
Anesthesiology; 2019 Jan; 130(1):41-54. PubMed ID: 30550426
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacological Treatment of Malignant Hyperthermia: Update 2019].
Schuster F; Johannsen S
Anasthesiol Intensivmed Notfallmed Schmerzther; 2019 Sep; 54(9):549-558. PubMed ID: 31525788
[TBL] [Abstract][Full Text] [Related]
38. Malignant hyperthermia: presymptomatic screening and treatment 2011.
Urwyler A
Eur J Anaesthesiol; 2011 Apr; 28(4):237-9. PubMed ID: 21389807
[No Abstract] [Full Text] [Related]
39. Management of otolaryngic patients susceptible to malignant hyperthermia without dantrolene.
Derkay CS; Grundfast KM
Otolaryngol Head Neck Surg; 1991 Nov; 105(5):680-6. PubMed ID: 1754251
[TBL] [Abstract][Full Text] [Related]
40. Effects of azumolene on normal and malignant hyperthermia-susceptible skeletal muscle.
Sudo RT; Carmo PL; Trachez MM; Zapata-Sudo G
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):308-16. PubMed ID: 18047479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
